<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001063</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 290</org_study_id>
    <secondary_id>11266</secondary_id>
    <nct_id>NCT00001063</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks</brief_title>
  <official_title>A Phase II Randomized Study of the Virologic and Immunologic Effects of d4T vs Zidovudine Plus d4T vs Zidovudine Plus Ddl in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and Greater Than 12 Weeks Zidovudine Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare the effect of stavudine (d4T) alone or with zidovudine (AZT) versus didanosine&#xD;
      (ddI) alone or with AZT on CD4 counts, HIV RNA levels, and viral load in HIV-infected&#xD;
      patients [AS PER AMENDMENT 3/21/97: To compare the effects of d4T alone versus ddI alone&#xD;
      versus AZT plus ddI]. To compare the safety of d4T/AZT. AS PER AMENDMENT 3/21/97: To evaluate&#xD;
      the pharmacokinetic interactions of AZT and d4T both at an extracellular and intracellular&#xD;
      level.&#xD;
&#xD;
      Although AZT and ddI can delay the advancement of HIV disease, the benefit of either of these&#xD;
      drugs has proven to be only temporary. d4T, a new nucleoside analog with a favorable toxicity&#xD;
      profile and demonstrated activity against HIV, offers an additional therapeutic option. It is&#xD;
      reasonably assumed that the benefit of an antiretroviral agent in terms of delaying clinical&#xD;
      disease progression is directly related to its ability to achieve and sustain viral&#xD;
      suppression; thus, this study measures effects on viral load and CD4 count.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although AZT and ddI can delay the advancement of HIV disease, the benefit of either of these&#xD;
      drugs has proven to be only temporary. d4T, a new nucleoside analog with a favorable toxicity&#xD;
      profile and demonstrated activity against HIV, offers an additional therapeutic option. It is&#xD;
      reasonably assumed that the benefit of an antiretroviral agent in terms of delaying clinical&#xD;
      disease progression is directly related to its ability to achieve and sustain viral&#xD;
      suppression; thus, this study measures effects on viral load and CD4 count.&#xD;
&#xD;
      Patients are randomized in a blinded fashion to receive AZT or placebo in combination with&#xD;
      open-label d4T or ddI for up to 48 weeks. AS PER AMENDMENT 3/21/97: The study is now composed&#xD;
      of three arms: open-label d4T versus open-label ddI plus blinded AZT placebo versus blinded&#xD;
      AZT plus open-label ddI. Patients originally assigned to the d4T + AZT arm, which was closed&#xD;
      10/96, will be given the option of discontinuing AZT and remaining on d4T monotherapy or&#xD;
      discontinuing all study drugs. In addition, all study participants will be asked to&#xD;
      participate in a pharmacology substudy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">November 1997</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required for patients whose CD4 count falls below 200 cells/mm3:&#xD;
&#xD;
          -  PCP prophylaxis with TMP/SMX, aerosolized pentamidine, or dapsone.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Atovaquone, IV pentamidine, trimethoprim-dapsone, clindamycin-primaquine,&#xD;
             trimetrexate, or TMP/SMX for acute PCP.&#xD;
&#xD;
          -  Topical antifungals, clotrimazole, ketoconazole, fluconazole, and amphotericin B for&#xD;
             mucosal and esophageal candidiasis.&#xD;
&#xD;
          -  Itraconazole.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Pyrazinamide.&#xD;
&#xD;
          -  Clofazimine.&#xD;
&#xD;
          -  Clarithromycin.&#xD;
&#xD;
          -  Azithromycin.&#xD;
&#xD;
          -  Ethambutol.&#xD;
&#xD;
          -  Amikacin.&#xD;
&#xD;
          -  Ciprofloxacin.&#xD;
&#xD;
          -  Ofloxacin.&#xD;
&#xD;
          -  Pyrimethamine.&#xD;
&#xD;
          -  Sulfadiazine.&#xD;
&#xD;
          -  Clindamycin.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  G-CSF.&#xD;
&#xD;
          -  Acyclovir (up to 1000 mg/day).&#xD;
&#xD;
          -  Erythropoietin.&#xD;
&#xD;
          -  Antibiotics for bacterial infections.&#xD;
&#xD;
          -  Antipyretics.&#xD;
&#xD;
          -  Analgesics.&#xD;
&#xD;
          -  Antiemetics.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Local radiation therapy.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  CD4 count 300-600 cells/mm3.&#xD;
&#xD;
          -  More than 12 weeks (was 24 weeks, AMENDED 3/31/96) of total prior AZT ( &gt; 500 mg/day&#xD;
             without serious adverse event). Subjects must be actively taking ZDV for at least 4&#xD;
             continuous weeks up to the time of study entry.&#xD;
&#xD;
          -  No prior or current history of AIDS.&#xD;
&#xD;
          -  No active opportunistic infection.&#xD;
&#xD;
          -  Life expectancy of at least 2 years.&#xD;
&#xD;
          -  Consent of patient and parent or guardian if less than 18 years of age.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Protocol is approved for prisoner enrollment.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Malignancy requiring systemic cytotoxic chemotherapy.&#xD;
&#xD;
          -  Serious underlying medical condition other than HIV that would reduce life expectancy&#xD;
             to &lt; 2 years.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretrovirals other than study drugs.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Unexplained temperature &gt;= 38.5 C for 7 days or chronic diarrhea (&gt;= three stools&#xD;
             daily) for 15 days, if occurring within 30 days prior to study entry.&#xD;
&#xD;
          -  History of acute or chronic pancreatitis.&#xD;
&#xD;
          -  History of grade 2 or higher peripheral neuropathy.&#xD;
&#xD;
          -  History of grade 3 or worse intolerance to 500-600 mg/day AZT.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        (within 30 days prior to study entry)&#xD;
&#xD;
          -  Prior ddI, ddC, 3TC or d4T (more than 2 weeks total).&#xD;
&#xD;
          -  Non-nucleoside reverse transcriptase inhibitor or protease inhibitor.&#xD;
&#xD;
          -  Biologic response modifiers such as interferon and IL-2.&#xD;
&#xD;
          -  Other experimental therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Havlir D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Richman D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Pollard R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Friedland G</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford CRS</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd, Avrc Crs</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Med. Ctr. CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Med. Ctr., ACTU</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Florida Jacksonville NICHD CRS</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Hawaii at Manoa, Leahi Hosp.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hosp. CORE Ctr.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weiss Memorial Hosp.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Wishard Memorial</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hosp. of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Hemophilia Treatment Ctr.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ACTG CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bmc Actg Crs</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Med. Ctr., ACTG CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Med. Ctr., Div. of Infectious Diseases</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, ACTU</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis ConnectCare, Infectious Diseases Clinic</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>d4T+AZT--unexpected CD4 drop seen in study. AIDS Treat News. 1996 Dec 20;(No 261):1.</citation>
    <PMID>11364024</PMID>
  </reference>
  <reference>
    <citation>Shaefer M, Hardy WD, Shaker-Irwin L, Williams V, Maude C, Thommes J, Graham N. HIV viral load response in subjects switched from zidovudine (ZDV)-containing to stavudine (D4T)-containing regimens in the Pacific Oaks Population Study (POPS). Int Conf AIDS. 1998;12:57 (abstract no 12228)</citation>
  </reference>
  <reference>
    <citation>Havlir DV, Friedland G, Pollard R, Tierney C, Smeaton L, Fox L, Richman DD. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleosides: report of two randomized trials (ACTG 290 and 298). Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:79 (abstract no 2)</citation>
  </reference>
  <reference>
    <citation>Cadman J. 2, 4, 6, 8, who's afraid to phosphorylate? GMHC Treat Issues. 1998 Feb;12(2):6-8.</citation>
    <PMID>11365218</PMID>
  </reference>
  <reference>
    <citation>Havlir DV, Tierney C, Friedland GH, Pollard RB, Smeaton L, Sommadossi JP, Fox L, Kessler H, Fife KH, Richman DD. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis. 2000 Jul;182(1):321-5. doi: 10.1086/315683. Epub 2000 Jul 6.</citation>
    <PMID>10882616</PMID>
  </reference>
  <reference>
    <citation>Sommadossi JP, Zhou XJ, Moore J, Havlir DV, Friedland G, Tierney C, Smeaton L, Fox L, Richman D, Pollard R. Impairment of stavudine (d4T) phosphorylation in patients receiving a combination of zidovudine (ZDV) and d4T (ACTG 290). Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:79 (abstract no 3)</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Didanosine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Stavudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

